Noramco CEO Lee Karras discusses $25 million Halo investment with PharmTech

The Noramco Group announced a $25 million investment in Halo Pharma to expand the company’s sterile injectable capabilities. Lee Karras, CEO of the Noramco Group, spoke with Pharmaceutical Technology about the news and how it will help address the ongoing capacity shortages in the market. 

You can watch the interview at https://www.pharmtech.com/view/dcat-week-2025-expanding-sterile-injectables-capacity